A new study from Massachusetts Institute of Technology implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation.
Scientists often test drugs in mice. Now some cancer patients are doing the same—with the hope of curing their own disease. They are paying a private lab to breed mice that carry bits of their own tumors so treatments can be tried first on the customized rodents. The idea is to see which drugs might work best on a specific person's cancer.
As the health care industry is undergoing a rapid transformation driven by evolving economic and regulatory demands, the biopharmaceutical industry also faces numerous challenges in meeting the needs of patients around the globe. Emerging markets are faced with the challenges of ensuring access to innovative, personalized treatments for patients with critical or rare conditions.
Nearly half of all U.S. adults, nearly 117 million individuals, are living with one or more chronic health conditions. This has become the age of chronic disease, and achieving better outcomes depends on developing tools for research and clinical care that efficiently and accurately address the complex diseases we face today.
Understanding how nitrite can improve conditions such as hypertension, heart attack and stroke has been the object of worldwide research studies. New research from Wake Forest Univ. has potentially moved the science one step closer to this goal. In a recently published paper, the team shows deoxygenated hemoglobin is indeed responsible for triggering the conversion of nitrite to nitric oxide, a process that affects blood flow and clotting.
Growing resistance to malaria drugs in Southeast Asia is caused by a single mutated gene inside the disease-causing Plasmodium falciparum parasite. This finding provides public health officials around the world with a way to look for pockets of emerging resistance and potentially eliminate them before they spread.
Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects.
Malaria parasites invade human red blood cells, which they bring to burst and infect others. Researchers at the University of Basel and the Swiss Tropical and Public Health Institute called nano imitations of host cell membranes have developed that deceive and trick the pathogen. This could lead to novel therapeutic and vaccine strategies against malaria and other infectious diseases.
One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. Now, researchers have developed a non–surgical injection of programmable biomaterial to do so.
Penicillin, the wonder drug discovered in 1928, works in ways that are still mysterious almost a century later. One of the oldest and most widely used antibiotics, it attacks enzymes that build the bacterial cell wall, a mesh that surrounds the bacterial membrane and gives the cells their integrity and shape. Once that wall is breached, bacteria die, allowing us to recover from infection.
The flu vaccine may not be very effective this winter, according to U.S. health officials who worry this may lead to more serious illnesses and deaths. Flu season has begun to ramp up, and officials say the vaccine does not protect well against the dominant strain seen most commonly so far this year. That strain tends to cause more deaths and hospitalizations, especially in the elderly.
Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don’t get to the root cause of the condition. Now, for the first time, scientists are reporting a new approach to defeating asthma by targeting the trigger—the allergen—before it can spark an attack. They describe their new compound, which they tested on rats, in the Journal of Medicinal Chemistry.
The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus's ability to cause AIDS. The Oxford Univ.-led study also indicates that people infected by HIV are likely to progress to AIDS more slowly—in other words the virus becomes less “virulent”—because of widespread access to antiretroviral therapy (ART).
IBM has engineered a way for everyone to join the fight against Ebola—by donating processing time on their personal computers, phones or tablets to researchers. IBM has teamed with scientists at Scripps Research Institute in southern California on a project that aims to combine the power of thousands of small computers, to each attack tiny pieces of a larger medical puzzle that might otherwise require a supercomputer to solve.
Declaring the "fight is nowhere close to being over," President Barack Obama on Tuesday heralded strides in the effort to confront Ebola in West Africa and in protecting the U.S. against the spread of the deadly virus. He said squelching the disease remains an urgent priority even if the American public's attention has shifted elsewhere.
The White House says the Obama administration is making strides in the fight against Ebola, citing an expanded hospital network and testing capacity at home and gains confronting the deadly disease in West Africa. To sustain that, President Barack Obama was prodding Congress Tuesday to approve his request for $6.2 billion in emergency spending against the outbreak.
Researchers can now explore viruses, bacteria and components of the human body in more detail than ever before with software developed at The Scripps Research Institute. In a study published online in Nature Methods, the researchers demonstrated how the software, called cellPACK, can be used to model viruses such as HIV.
The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found. The trial included patients with melanoma or cancers of the lung, kidney, colon, GI tract, or head and neck, whose tumors were evaluated for PD-L1 expression by a novel assay.
Toxoplasma gondii is a common parasite often spread by cats. Most people who are infected in Europe or North America show no symptoms at all, and only a few suffer from encephalitis or ocular toxoplasmosis, which can cause blindness. However, in South America, toxoplasmosis is associated with much more severe symptoms.
Many older people silently harbor a blood "pre-cancer"—a gene mutation acquired during their lifetime that could start them on the path to leukemia, lymphoma or other blood disease, scientists have discovered. It opens a new frontier on early detection and possibly someday preventing these cancers, which become more common with age.
An experimental Ebola vaccine appears safe and triggered signs of immune protection in the first 20 volunteers to test it, U.S. researchers reported. The vaccine is designed to spur the immune system's production of anti-Ebola antibodies, and people developed them within four weeks of getting the shots at the National Institutes of Health.
Dr. Denham Harman, a renowned scientist who developed the most widely accepted theory on aging that's now used to study cancer, Alzheimer's disease and other illnesses, has died in Nebraska at age 98. Harman, who worked into his mid-90s at the Univ. of Nebraska Medical Center died after a brief illness at a hospital in Omaha.
The body responds to tuberculosis infection by locking the bacterial offenders into tiny clusters of immune cells called granulomas, which are a hallmark of the disease. This containment strategy succeeds at first, but eventually the bacteria manage to break out of these intercellular jails and spread throughout the body.
Scientists from Lawrence Berkeley National Laboratory have learned new details about how an important tumor-suppressing protein, called p53, binds to the human genome. As with many things in life, they found that context makes a big difference. The researchers mapped the places where p53 binds to the genome in a human cancer cell line.
The next Ebola or the next SARS. Maybe even the next HIV. Even before the Ebola epidemic in West Africa is brought under control, public health officials are girding for the next health disaster. Ebola sprang from one of those blind spots, in an area that lacks the health systems needed to detect an outbreak before it becomes a crisis.